Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 2, 2026

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

Predictive and prognostic factors for gliomas.

François Ducray1, Ahmed Idbaih, Xiao-Wei Wang

  • 1Hôpital Neurologique, Service de Neurologie B, Lyon, France.

Expert Review of Anticancer Therapy
|May 11, 2011
PubMed
Summary

Gliomas require better molecular characterization for improved treatment. Key markers like 1p/19q codeletion and IDH1 mutations significantly impact prognosis and treatment response in glioma patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BRAF-MEK inhibition in a giant BRAF-mutant Rathke cleft cyst: Diagnostic challenges and clinical implications for BRAF testing.

Neuro-oncology practice·2026
Same author

Intensified Rituximab, Methotrexate, Procarbazine, and Cytarabine (R-MPVA) Regimen With Sequential Addition of Etoposide to R-MPV and Ifosfamide to R-AraC for Newly Diagnosed Primary CNS Lymphoma Patients Aged Between 60 and 70 Years: An LOC Network Study.

Hematological oncology·2026
Same author

Magnetic Resonance Imaging Features in Intramedullary Tumors: A Pictorial Review.

Biomedicines·2026
Same author

Efficacy of MAPK inhibitors in children with neurodegenerative Langerhans cell histiocytosis: Results from the European Consortium for Histiocytosis.

HemaSphere·2026
Same author

Efficacy and Tolerance of Cladribine for Non-Langerhans Cell Histiocytosis.

European journal of haematology·2026
Same author

Early brain biopsy in neurological diseases of unknown etiology improves functional outcome.

European journal of internal medicine·2026

Area of Science:

  • Neuro-oncology
  • Molecular Pathology
  • Genetics

Background:

  • Gliomas, especially glioblastoma, remain challenging despite advances.
  • Current histological classification needs molecular markers for better outcomes.
  • Key markers include 1p/19q codeletion, MGMT promoter methylation, and IDH1/IDH2 mutations.

Purpose of the Study:

  • To highlight the importance of molecular markers in glioma classification and treatment.
  • To discuss the prognostic and predictive value of specific genetic alterations.
  • To emphasize the need for integrated molecular studies in gliomas.

Main Methods:

  • Review of current molecular markers used in glioma diagnosis and prognosis.
  • Discussion of the impact of 1p/19q codeletion, MGMT methylation, and IDH1/IDH2 mutations.

More Related Videos

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
05:45

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

Related Experiment Videos

Last Updated: Jun 2, 2026

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
05:45

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

  • Reference to recent integrated genomic, transcriptomic, and epigenetic studies.

    • Main Results:

    • 1p/19q codeletion predicts better response in oligodendroglial tumors.
    • MGMT promoter methylation correlates with better response to chemoradiotherapy in glioblastoma.
    • IDH1/IDH2 mutations are inversely correlated with grade and are strong independent predictors of survival.

    Conclusions:

    • Molecular markers are crucial for refining glioma classification and predicting treatment response.
    • Integrated molecular profiling is essential for understanding glioblastoma heterogeneity.
    • Extending comprehensive molecular analysis to lower-grade gliomas is recommended.